BioCentury | Dec 5, 2017
Financial News

Heron raises $150M in follow-on

...raised $150 million in a follow-on underwritten by Cantor Fitzgerald. The company markets Sustol granisetron extended release (APF530...
...with the anti-inflammatory meloxicam formulated using Biochronomer. Heron lost $1.65 (10%) to $15.50 on Tuesday. Mary Romeo APF530 aprepitant Cinvanti granisetron extended release HTX-011 HTX-019 Sustol Heron...
BioCentury | Jan 19, 2017
Financial News

Heron raises $150M in follow-on

...$12.80 on Wednesday, before it proposed the offering after market hours. Heron markets Sustol granisetron extended release (APF530...
...with the anti-inflammatory meloxicam formulated using Biochronomer. Heron gained $1.05 to $13.85 on Thursday. Jaime De Leon HTX-011 HTX-019 Sustol Heron...
BioCentury | Oct 3, 2016
Finance

Dressed in black

...NYSE:GSK) China approves Cervarix to prevent cervical cancer Heron Therapeutics Inc. (NASDAQ:HRTX) FDA approves Sustol granisetron extended release...
BioCentury | Aug 15, 2016
Clinical News

Sustol granisetron extended release regulatory update

...FDA approved an NDA from Heron for Sustol granisetron to prevent acute and delayed nausea and...
...prevent acute and delayed nausea and vomiting associated with chemotherapy in combination with other antiemetics. Sustol...
...Biochronomer drug delivery technology. Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif. Product: Sustol granisetron extended release ( APF530...
BioCentury | Aug 10, 2016
Company News

FDA approves Heron's Sustol

...Heron Therapeutics Inc. (NASDAQ:HRTX) said FDA approved Sustol granisetron extended release ( APF530 ) in adults in combination...
...quarter. On a conference call Wednesday, Heron President and CCO Robert Rosen declined to disclose Sustol's...
...time." FDA will require the company to conduct a randomized, active-controlled post-marketing trial to evaluate Sustol's...
BioCentury | Jan 25, 2016
Clinical News

Sustol granisetron extended release regulatory update

...Heron said FDA now expects to complete its review of an NDA from Heron for Sustol...
...for chemotherapy-induced nausea and vomiting (CINV) in late February. The PDUFA date was Jan. 17. Sustol...
...BioCentury, April 1, 2013). Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif. Product: Sustol granisetron extended release ( APF530...
BioCentury | Jan 11, 2016
Finance

Sowing season

...emtricitabine / tenofovir alafenamide fumarate (R/F/TAF) HIV PDUFA date 3/1/16 Heron Therapeutics Inc. (NASDAQ:HRTX) Sustol granisetron extended release...
BioCentury | Sep 28, 2015
Clinical News

Granisetron extended release regulatory update

...FDA accepted for review an NDA from Heron for Sustol granisetron extended release to prevent acute and delayed...
...for Sustol (see BioCentury, April 1, 2013). Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif. Product: Granisetron extended release...
...1, 2013). Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif. Product: Granisetron extended release ( Sustol ) ( APF530...
BioCentury | Jul 27, 2015
Clinical News

Granisetron extended release regulatory update

...Heron resubmitted an NDA to FDA for Sustol granisetron extended release to prevent acute and delayed chemotherapy-induced nausea...
...data from the double-blind, U.S. Phase III MAGIC trial, which showed that 500 mg subcutaneous Sustol...
...delivery technology. Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif. Product: Granisetron extended release ( Sustol ) ( APF530...
BioCentury | Jul 20, 2015
Clinical News

Sustol: Phase III data

...III MAGIC trial in 942 patients receiving highly emetogenic chemotherapy showed that 500 mg subcutaneous Sustol...
...NDA to FDA for Sustol in mid-2015. FDA has issued 2 complete response letters for Sustol...
...see BioCentury, April 1, 2013). Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif. Product: Sustol ( APF530...
Items per page:
1 - 10 of 64